RNXT vs. CTOR, FATE, HURA, CGEN, ACOG, GNLX, IKT, SCLX, CHRS, and CGTX
Should you be buying RenovoRx stock or one of its competitors? The main competitors of RenovoRx include Citius Oncology (CTOR), Fate Therapeutics (FATE), TuHURA Biosciences (HURA), Compugen (CGEN), Alpha Cognition (ACOG), Genelux (GNLX), Inhibikase Therapeutics (IKT), Scilex (SCLX), Coherus Oncology (CHRS), and Cognition Therapeutics (CGTX). These companies are all part of the "pharmaceutical products" industry.
RenovoRx vs. Its Competitors
RenovoRx (NASDAQ:RNXT) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.
In the previous week, RenovoRx had 5 more articles in the media than Citius Oncology. MarketBeat recorded 7 mentions for RenovoRx and 2 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 0.88 beat RenovoRx's score of 0.18 indicating that Citius Oncology is being referred to more favorably in the news media.
Citius Oncology has lower revenue, but higher earnings than RenovoRx.
RenovoRx has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Citius Oncology has a beta of 3, suggesting that its share price is 200% more volatile than the S&P 500.
3.1% of RenovoRx shares are owned by institutional investors. Comparatively, 70.5% of Citius Oncology shares are owned by institutional investors. 9.1% of RenovoRx shares are owned by insiders. Comparatively, 4.6% of Citius Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
RenovoRx presently has a consensus price target of $7.50, suggesting a potential upside of 693.65%. Citius Oncology has a consensus price target of $3.00, suggesting a potential upside of 40.65%. Given RenovoRx's stronger consensus rating and higher possible upside, equities research analysts clearly believe RenovoRx is more favorable than Citius Oncology.
Citius Oncology's return on equity of -51.93% beat RenovoRx's return on equity.
Summary
RenovoRx beats Citius Oncology on 6 of the 11 factors compared between the two stocks.
Get RenovoRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNXT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RNXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
RenovoRx Competitors List
Related Companies and Tools
This page (NASDAQ:RNXT) was last updated on 8/28/2025 by MarketBeat.com Staff
MarketBeat All Access